Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

Summary

This study aims to evaluate the use of teclistamab in systemic AL amyloidosis and answer whether teclistamab can improve the rate of complete hematological response. This is a single-arm, multi-center, prospective study. Participants will receive the single drug teclistamab, which the investigator deems the best choice.

Timeline

Start

2025-03-29

Primary completion

2025-12-31

Completion

2026-12-31

Drugs

Indications